Other pathways (e.g., IFN-γ, interleukin 10 (IL-10)) and targets (e.g., JAK family tyrosine kinases and STAT family proteins) can lead to better and more tunable effects of CAR-T therapy acting indirectly on the IL-6 pathway and not only regulating CAR-T action, but also controlling the tumor microenvironment [56,57]. The gene discussed is IFNG; the disease is neoplasm.